High‐dose bendamustine plus brentuximab combination is effective and has a favourable toxicity profile in the treatment of refractory and relapsed Hodgkin lymphoma. (June 2017) - Cerchione, C.; Di Perna, M.; Della Pepa, R.; Pugliese, N.; Pane, F.; Picardi, M.